What is the official website of Novartis Israel ?

The official website of Novartis Israel is https://www.novartis.com/il-he/.

What is Novartis Israel's cybersecurity risk score?

Novartis Israel has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Israel experienced?

According to Rankiteo, Novartis Israel currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Israel been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Israel has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Israel have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Israel is not certified under SOC 2 Type 1.

Does Novartis Israel have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Israel does not hold a SOC 2 Type 2 certification.

Does Novartis Israel comply with GDPR ?

According to Rankiteo, Novartis Israel is not listed as GDPR compliant.

Does Novartis Israel have PCI DSS certification ?

According to Rankiteo, Novartis Israel does not currently maintain PCI DSS compliance.

Does Novartis Israel comply with HIPAA ?

According to Rankiteo, Novartis Israel is not compliant with HIPAA regulations.

Does Novartis Israel have ISO 27001 certification ?

According to Rankiteo,Novartis Israel is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Israel operate in ?

Novartis Israel operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Israel have ?

Novartis Israel employs approximately 41 people worldwide.

Does Novartis Israel own any subsidiaries ?

Novartis Israel presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Israel have ?

Novartis Israel's official LinkedIn profile has approximately 980 followers.

What is the NAICS classification code for Novartis Israel ?

Novartis Israel is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Israel have a Crunchbase profile ?

No, Novartis Israel does not have a profile on Crunchbase.

Does Novartis Israel have a LinkedIn profile ?

Yes, Novartis Israel maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-israel.

How many cybersecurity incidents has Novartis Israel experienced ?

As of August 18, 2026, Rankiteo reports that Novartis Israel has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Israel have ?

Novartis Israel has an estimated 5,729 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Israel faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Israel

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Israel Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Around 108,000 people of more than 140 nationalities work at Novartis around the world. See our community guidelines: http://bit.ly/2JnT2CP

Novartis Israel A.I CyberSecurity Scoring

Scoring History

Novartis Israel

Novartis Israel CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Israel

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Israel Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Israel

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident Types Novartis Israel vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident History - Novartis Israel (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Israel Subsidiaries

Novartis Israel

Pharmaceutical Manufacturing

Website: https://www.novartis.com/il-he/

Company Size: 41

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Loading…

Novartis Israel Similar Companies

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

Novartis Israel CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 03, 2025 08:00 AM

JPMorgan's tech team hired an Amazon director and Pfizer executive as MDs

JPMorgan has been hiring multiple senior technologists, but they're not all coming from finance. Two new managing directors (MDs),...

Read Article

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

July 19, 2021 07:00 AM

Rapid7 acquires IntSights for close to $400 million

The Israeli cybersecurity company is set to become Rapid7's R&D center in Israel)

Read Article

July 15, 2021 07:00 AM

Rapid7 in advanced talks to acquire Israel's IntSights for $350 million

The Israeli cybersecurity company has raised $70 million to date and counts Forbes, Novartis and Ford among its clients)

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-9693

SUMMARY

Mattermost versions 10.11.x <= 10.11.20, 11.7.x <= 11.7.5 Mattermost fails to remove thread membership records when a user is removed from or leaves a team, which allows a previously removed user who is later re-invited to the team to view private channel thread root post content and metadata via the team threads API.. Mattermost Advisory ID: MMSA-2026-00682

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: 3.5)

cvss3

Base Score: 3.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.1

REFERENCES

https://mattermost.com/security-updates

CVE-2026-75587

SUMMARY

Mattermost Desktop App versions <=6.2 6.2.2.0 fail to redact the pre-auth secret when generating a diagnostics report, which allows a local attacker with access to a user's diagnostics report or log files to obtain the plaintext pre-auth secret configured for a connected server via inspecting the Server Connectivity (Step-3) diagnostics output. Mattermost Advisory ID: MMSA-2026-00716

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: 3.6)

cvss3

Base Score: 3.6

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:C/C:L/I:N/A:N

Impact Score

1.4

Exploitability

1.8

REFERENCES

https://mattermost.com/security-updates

CVE-2026-75078

SUMMARY

A security flaw has been discovered in SourceCodester Class and Exam Timetabling System 1.0. This affects an unknown part of the file /BSHRM1.php. Performing a manipulation of the argument course results in cross site scripting. Remote exploitation of the attack is possible. The exploit has been released to the public and may be used for attacks.

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-67961

SUMMARY

An issue in O2OA v.10.0.2 allows a local attacker to execute arbitrary code via the the sandbox mechanism of the Invoke script execution.

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-67919

SUMMARY

An issue in Halo 2.25.4 allows a remote attacker to execute arbitrary code via the PluginEndpoint.java, installFromUri method, and DefaultPluginApplicationContextFactory components

Published

Date2026-08-17

Updated

Date2026-08-17

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…